Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Angiogenesis. 2013 Oct 29;17(3):563–571. doi: 10.1007/s10456-013-9403-4

Figure 4. Effect of purified exogenous WT tumor gangliosides on tumor angiogenesis.

Figure 4

105 WT or DKO cells were co-injected s.c. with or without 100 pmol WT tumor gangliosides (G) into groups of five mice. Tumor growth curves (Panel A) and tumor weights at the day 21/22 endpoint (Panel B) are shown (key: NS: p>0.05; *: p=0.07; **: P≤0.0001). Panel C, tumor site vasculature (day 14): (control) PBS alone, (DKO) DKO tumor identified by the arrow, (WT) WT tumor, (DKO+G) DKO tumor cells co-injected with 100 pmol WT tumor gangliosides. Panel D: histopathology of equal size (small) WT and DKO tumors. Upper row, H&E staining; lower row, CD31 staining. Tumors were harvested on days 7–9 (WT), (WT+G), and (DKO+G), and day 14 (DKO). Magnification: 200×; bars represent 100µm.